Agency Forms Undergoing Paperwork Reduction Act Review, 26257-26258 [2010-11180]
Download as PDF
<![CDATA[
26257
Federal Register / Vol. 75, No. 90 / Tuesday, May 11, 2010 / Notices
ESTIMATE OF ANNUALIZED BURDEN HOURS—Continued
Respondents
state epidemiologists
Number of
respondents
Form
National Respiratory & Enteric Virus Surveillance System (NREVSS) ..........................
Rabies (electronic) ...........................................................................................................
Rabies (paper) .................................................................................................................
Waterborne Diseases Outbreak Form .............................................................................
Cholera and other Vibrio illnesses ..................................................................................
Outbreak Report of Suspected Viral Gastroenteritis (Clicivirus surveillance) .................
Listeria Case Form ..........................................................................................................
HABISS data entry form ..................................................................................................
HABISS monthly reporting form ......................................................................................
Dated: May 5, 2010.
Maryam I. Daneshvar,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
[FR Doc. 2010–11178 Filed 5–10–10; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day-10–09BQ]
Agency Forms Undergoing Paperwork
Reduction Act Review
The Centers for Disease Control and
Prevention (CDC) publishes a list of
information collection requests under
review by the Office of Management and
Budget (OMB) in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
requests, call the CDC Reports Clearance
Officer at (404) 639–5960 or send an email to omb@cdc.gov. Send written
comments to CDC Desk Officer, Office of
Management and Budget, Washington,
DC or by fax to (202) 395–5806. Written
comments should be received within 30
days of this notice.
emcdonald on DSK2BSOYB1PROD with NOTICES
Proposed Project
Examining In-vehicle Exposures to
Air Pollutants and Corresponding
Health Outcomes of Commuters—
New—National Center for
Environmental Health, (NCEH) and
Agency for Toxic Substances and
Disease Registry (ATSDR), Centers for
Disease Control and Prevention, (CDC).
VerDate Mar<15>2010
19:22 May 10, 2010
Jkt 220001
Background and Brief Description
Numerous studies have found
associations between ambient fine
particulate matter (PM2.5) and adverse
cardiovascular outcomes. Several recent
epidemiologic studies suggest that
vehicle-related emissions, in particular,
may be linked to many of the these
adverse effects and that specific subpopulations may be more susceptible to
health risks due to their enhanced
exposures to vehicle-related PM2.5
sources. Commuters are a potentially
susceptible, yet poorly characterized,
sub-population. Importantly, recent
epidemiologic studies indicate that
specific sub-groups, including those
with asthma, may be at risk to cardio
respiratory health effects due to their
pre-existing health condition. A more
complete understanding of in-vehicle
exposures for the commuter population,
especially those with asthma, is
therefore becoming increasingly
necessary as commuting durations and
roadway congestion have steadily
increased throughout the U.S. during
the last 20 years. The National Center
for Environmental Health (NCEH),
Centers for Disease Control and
Prevention (CDC) will conduct this
study to characterize in-vehicle
exposures to traffic-related air
pollutants among commuters, with and
without asthma, and any health impacts
that these exposures may have on the
commuter.
A total of 40 participants (20 adults
with physician-diagnosed asthma and
20 healthy adults) living in the Atlanta
metro area will be recruited for
participation in this study. Participants
will be excluded if they meet specific
criteria including: ever being diagnosed
with severe asthma, ever suffering a
PO 00000
Frm 00073
Fmt 4703
Sfmt 4703
Number of
responses per
respondent
90
50
3
57
450
20
53
10
10
52
12
12
1
1
5
1
12
12
Average burden
per response
(in hours)
10/60
8/60
15/60
20/60
20/60
5/60
30/60
8
30/60
myocardial infarction, smoking tobacco
products, or ever being diagnosed with
a pulmonary disease such as
emphysema, chronic obstructive
pulmonary disorder (COPD), or any type
of lung cancer, will be excluded.
Prior to their scheduled commute,
participants will complete a one-time
baseline questionnaire to assess medical
history and general exposures.
Additionally, a short symptom diary
recording any respiratory symptoms
will be completed by the participant
prior to the commute and health
measurements for lung function, lung
inflammatory markers, heart rate, and
biomarkers of systemic inflammation
will be conducted by a trained field
technician. In-vehicle exposures to
particulate matter and other air
pollutants will then be measured for all
participants during their commute.
After the commute, the symptom diary
and health measurements will be
conducted again to assess any potential
changes in respiratory and
cardiovascular health effects. Each
participant will conduct the commute
two times during the study year. The
information learned from the health
measurements and diary entries before
and after the commute will be important
in better understanding the potential
acute health impacts associated with
exposures to in-vehicle traffic pollutants
and respiratory and cardiovascular
health, and whether urban commuters—
especially those with asthma—should
be viewed as a susceptible subpopulation given their enhanced
exposures to PM2.5 and gas-phase
pollutants.
There is no cost to participants other
than their time. The estimated annual
burden hours are 180 hours.
E:\FR\FM\11MYN1.SGM
11MYN1
26258
Federal Register / Vol. 75, No. 90 / Tuesday, May 11, 2010 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS
No. of
respondents
Respondents
Instrument type
Eligible participants .........................................
Baseline questionnaire ...................................
Symptom survey ............................................
Scripted commute data collection ..................
Dated: May 5, 2010.
Maryam I. Daneshvar,
Reports Clearance Officer, Centers for Disease
Control and Prevention.
[FR Doc. 2010–11180 Filed 5–10–10; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of the Director; Notice of Charter
Renewal for the National Science
Advisory Board for Biosecurity
In accordance with Title 41 of the
U.S. Code of Federal Regulations,
Section 102–3.65(a), notice is hereby
given that the Charter for the National
Science Advisory Board for Biosecurity
(NSABB) was renewed for an additional
two-year period on April 7, 2010.
It is determined that NSABB is in the
public interest in connection with the
performance of duties imposed on the
Department of Health and Human
Services by law, and that these duties
can best be performed through the
advice and counsel of this group.
Inquiries may be directed to Jennifer
Spaeth, Director, Office of Federal
Advisory Committee Policy, Office of
the Director, National Institutes of
Health, 6701 Democracy Boulevard,
Suite 1000, Bethesda, Maryland 20892
(Mail code 4875), Telephone (301) 496–
2123, or spaethj@od.nih.gov.
Dated: May 4, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2010–11043 Filed 5–10–10; 8:45 am]
BILLING CODE 4140–01–P
emcdonald on DSK2BSOYB1PROD with NOTICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY: National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
VerDate Mar<15>2010
19:22 May 10, 2010
Jkt 220001
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
ADDRESSES:
Erythroid Progenitor Cell Line for
Hematological Disease Applications
Description of Invention: Plasmodium
vivax (malaria) is a significant health
concern in many parts of Asia, Latin
America, North Africa, and the Middle
East. There is a lack of continuous
culture systems for this pathogen. The
subject technology is an erythroid
progenitor continuous cell line (termed
CD36E) identified by erythroid markers
CD36, CD33, CD44, CD71, CD235, and
globoside. These CD36E cells are
heterozygous for Fya and Fyb (Duffy
antigen). Due to recent evidence that
Plasmodium vivax (P. vivax) can infect
erythroid progenitor cells (reference: YX
Ru et al. and T Panichakul et al.), these
cells can be potentially used for
culturing P. vivax and other species of
malaria. This in turn could aid
development of malaria related
treatments and/or products. In addition,
the cell line can also be used for other
hematological disease applications that
involve red blood cells or red blood cell
precursors. The CD36E cells also
produce alpha, beta, and chi
hemoglobin and therefore may be used
for research involving hemoglobin.
Applications:
PO 00000
Frm 00074
Fmt 4703
Sfmt 4703
No. of
responses per
respondent
40
40
40
1
5
2
Average
burden per
respondent
(in hours)
20/60
2/60
2
• Culture system for Plasmodium
species (malaria)
• Hematological diseases
Advantages: Immortalized erythroid
progenitor cell line.
Development Status: In vitro data can
be provided upon request.
Market:
• Malaria
• Anti-malaria drug screening
• Hematological diseases
• Hemoglobin
Inventors: Susan Wong, Neal S.
Young, Ning Zhi (NHLBI).
Relevant Publications:
1. YX Ru et al. Invasion of
erythroblasts by Pasmodium vivax: A
new mechanism contributing to malarial
anemia. Ultrastruct Pathol. 2009
Oct;33(5):236–242. [PubMed:
19895296].
2. T Panichakul et al. Production of
erythropoietic cells in vitro for
continuous culture of Plasmodium
vivax. Int J Parasitol. 2007
Dec;37(14):1551–1557. [PubMed:
17610880].
Patent Status: HHS Reference No. E–
151–2010/0—Research Tool. Patent
protection is not being pursued for this
technology.
Licensing Status: Available for
biological materials licensing.
Licensing Contact: Kevin W. Chang,
Ph.D.; 301–435–5018;
changke@mail.nih.gov.
Collaborative Research Opportunity:
The National Heart Lung and Blood
Institute, Hematology Branch, is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate, or
commercialize the CD36E cell line.
Please contact Cecilia Pazman, Ph.D., at
pazmance@mail.nih.gov for more
information.
Parvovirus B19 Codon Optimized
Structural Proteins for Vaccine and
Diagnostic Applications
Description of Invention: Parvovirus
B19 (B19V) is the only known
pathogenic human parvovirus. Infection
by this viral pathogen can cause
transient aplastic crisis in individuals
with high red cell turnover, pure red
cell aplasia in immunosuppressed
patients, and hydrops fetalis during
E:\FR\FM\11MYN1.SGM
11MYN1
]]>Agencies
[Federal Register Volume 75, Number 90 (Tuesday, May 11, 2010)]
[Notices]
[Pages 26257-26258]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-11180]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30Day-10-09BQ]
Agency Forms Undergoing Paperwork Reduction Act Review
The Centers for Disease Control and Prevention (CDC) publishes a
list of information collection requests under review by the Office of
Management and Budget (OMB) in compliance with the Paperwork Reduction
Act (44 U.S.C. Chapter 35). To request a copy of these requests, call
the CDC Reports Clearance Officer at (404) 639-5960 or send an e-mail
to omb@cdc.gov. Send written comments to CDC Desk Officer, Office of
Management and Budget, Washington, DC or by fax to (202) 395-5806.
Written comments should be received within 30 days of this notice.
Proposed Project
Examining In-vehicle Exposures to Air Pollutants and Corresponding
Health Outcomes of Commuters--New--National Center for Environmental
Health, (NCEH) and Agency for Toxic Substances and Disease Registry
(ATSDR), Centers for Disease Control and Prevention, (CDC).
Background and Brief Description
Numerous studies have found associations between ambient fine
particulate matter (PM2.5) and adverse cardiovascular
outcomes. Several recent epidemiologic studies suggest that vehicle-
related emissions, in particular, may be linked to many of the these
adverse effects and that specific sub-populations may be more
susceptible to health risks due to their enhanced exposures to vehicle-
related PM2.5 sources. Commuters are a potentially
susceptible, yet poorly characterized, sub-population. Importantly,
recent epidemiologic studies indicate that specific sub-groups,
including those with asthma, may be at risk to cardio respiratory
health effects due to their pre-existing health condition. A more
complete understanding of in-vehicle exposures for the commuter
population, especially those with asthma, is therefore becoming
increasingly necessary as commuting durations and roadway congestion
have steadily increased throughout the U.S. during the last 20 years.
The National Center for Environmental Health (NCEH), Centers for
Disease Control and Prevention (CDC) will conduct this study to
characterize in-vehicle exposures to traffic-related air pollutants
among commuters, with and without asthma, and any health impacts that
these exposures may have on the commuter.
A total of 40 participants (20 adults with physician-diagnosed
asthma and 20 healthy adults) living in the Atlanta metro area will be
recruited for participation in this study. Participants will be
excluded if they meet specific criteria including: ever being diagnosed
with severe asthma, ever suffering a myocardial infarction, smoking
tobacco products, or ever being diagnosed with a pulmonary disease such
as emphysema, chronic obstructive pulmonary disorder (COPD), or any
type of lung cancer, will be excluded.
Prior to their scheduled commute, participants will complete a one-
time baseline questionnaire to assess medical history and general
exposures. Additionally, a short symptom diary recording any
respiratory symptoms will be completed by the participant prior to the
commute and health measurements for lung function, lung inflammatory
markers, heart rate, and biomarkers of systemic inflammation will be
conducted by a trained field technician. In-vehicle exposures to
particulate matter and other air pollutants will then be measured for
all participants during their commute. After the commute, the symptom
diary and health measurements will be conducted again to assess any
potential changes in respiratory and cardiovascular health effects.
Each participant will conduct the commute two times during the study
year. The information learned from the health measurements and diary
entries before and after the commute will be important in better
understanding the potential acute health impacts associated with
exposures to in-vehicle traffic pollutants and respiratory and
cardiovascular health, and whether urban commuters--especially those
with asthma--should be viewed as a susceptible sub-population given
their enhanced exposures to PM2.5 and gas-phase pollutants.
There is no cost to participants other than their time. The
estimated annual burden hours are 180 hours.
[[Page 26258]]
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Average
No. of No. of burden per
Respondents Instrument type respondents responses per respondent (in
respondent hours)
----------------------------------------------------------------------------------------------------------------
Eligible participants.............. Baseline questionnaire..... 40 1 20/60
Symptom survey............. 40 5 2/60
Scripted commute data 40 2 2
collection.
----------------------------------------------------------------------------------------------------------------
Dated: May 5, 2010.
Maryam I. Daneshvar,
Reports Clearance Officer, Centers for Disease Control and Prevention.
[FR Doc. 2010-11180 Filed 5-10-10; 8:45 am]
BILLING CODE 4163-18-P
